LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $95.25.

A number of research firms have weighed in on LMAT. Lake Street Capital raised their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price for the company. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Finally, Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th.

Remove Ads

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 10.79% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of LeMaitre Vascular by 1.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,737 shares of the medical instruments supplier's stock valued at $3,293,000 after acquiring an additional 470 shares in the last quarter. Snowden Capital Advisors LLC raised its holdings in LeMaitre Vascular by 10.8% in the 4th quarter. Snowden Capital Advisors LLC now owns 7,733 shares of the medical instruments supplier's stock worth $713,000 after purchasing an additional 751 shares in the last quarter. Nicholas Investment Partners LP lifted its position in shares of LeMaitre Vascular by 4.3% in the 4th quarter. Nicholas Investment Partners LP now owns 51,597 shares of the medical instruments supplier's stock worth $4,754,000 after purchasing an additional 2,116 shares during the period. Occudo Quantitative Strategies LP boosted its stake in shares of LeMaitre Vascular by 20.0% during the 4th quarter. Occudo Quantitative Strategies LP now owns 3,413 shares of the medical instruments supplier's stock valued at $314,000 after purchasing an additional 569 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of LeMaitre Vascular by 96.8% during the fourth quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier's stock valued at $8,853,000 after buying an additional 47,250 shares during the period. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Trading Down 2.5 %

Shares of LMAT stock traded down $2.06 during trading hours on Wednesday, reaching $79.78. The stock had a trading volume of 283,349 shares, compared to its average volume of 156,497. The stock's fifty day simple moving average is $91.62 and its 200 day simple moving average is $94.22. The firm has a market capitalization of $1.80 billion, a PE ratio of 43.60, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular has a 12 month low of $62.39 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. As a group, equities research analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. This represents a $0.80 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.